Intracranial Atherosclerosis Not Linked to Amyloid – Medscape

A new study shows no association between intracranial atherosclerotic plaque and brain beta-amyloid deposition in a community-based cohort of older adults without dementia.

"We know vascular risk factors are associated with later dementia, but our current results suggest that the mechanism by which vascularrisk might act on dementia risk is probably not, at least entirely, through intracranial atherosclerosis," lead study author Rebecca Gottesman, MD, PhD, Johns Hopkins Hospital, Baltimore, Maryland, told Medscape Medical News.

The study was published online December 20 in JAMA Neurology.

"There has been some evidence that vascular risk factors are associated with elevated brain amyloid, and in particular, in some autopsy studiesthat cholesterol buildup in the arteries in the brain was associated with Alzheimer's-type changes," Gottesman explained.

"We wanted to study the relationship between atherosclerosis in the arteries of the brain in living individuals without dementia to see if it was associated with these Alzheimer's-type changes because this might identify an important potentially modifiable risk factor for Alzheimer's brain changes," she said.

For the study, researchers analyzed data from a subset of 300 individuals aged 70-90 years (mean age 76 years) without dementia from the Atherosclerosis Risk in Communities (ARIC) cohort study who underwent PET scanning to detect amyloid buildup. The same individuals also underwent brain MRI to evaluate intracranial atherosclerosis.

Results showed no evidence of an association between plaque presence and global cerebral beta-amyloid. Furthermore, modest stenosis of the intracranial vessels was not associated with amyloid levels.

"We had hypothesized that we might find evidence of an association between intracranial atherosclerosis and brain amyloid based on earlier studies," Gottesman said. "However, this was a cross-sectional analysis these sets of scans were basically done during the same time period for all study participants which means we may have failed to find an association because the relationship may take years to occur. It is also possible, however, that vascular risk factors themselves act on risk for dementia and Alzheimer's," she added.

Gottesman points out that intracranial atherosclerosis is known to be associated with dementia risk more broadly, emphasizing that more needs to be done to understand how this elevated risk occurs.

"We need to understand more about the longer-term effect of intracranial atherosclerosis and how it impacts dementia and Alzheimer's risk over years to decades. Also, it is important to understand if certain subgroups of people might be especially susceptible to adverse effects of having intracranial atherosclerosisand how stroke fits in with these relationships," she commented.

Gottesman says the current results should not be taken as evidence that vascular dementia and Alzheimer's have completely different causes.

"Intracranial atherosclerosis is just one type of vasculareffect in the brain, and other studies demonstrate that midlife vascular risk factors are more strongly associated with later-life cognition and even later-life brain amyloid, so we may just need to consider longer-term relationships between the two," she explained.

It could also be just one additional consequence of vascular risk factors that might act on the brain and on Alzheimer's risk in different ways, she added.

Furthermore, this study did not address how the relative amounts of intracranial atherosclerosis and brain amyloid each contribute to dementia risk, and thus, did not address how these affect clinically relevant dementia, Gottesman noted.

"We know there is a lot of overlap in the pathology of people with dementia, and other studies suggest that this applies to intracranial atherosclerosis and Alzheimer's changes in the brain in addition to other types of vascular changes that can be observed," she said.

The researchers suggest that potential mechanisms for an association between intracranial atherosclerosis and beta-amyloid may depend on a greater degree of stenosis than what was found in this generally healthy cohort or with a more cognitively impaired population at later stages in disease.

The ARIC study was funded by the National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), and US Department of Health and Human Services. Gottesman has reported receiving grants from the NIH/National Institute on Aging.

JAMA Neurol. Published online December 20, 2019. Abstract

For more Medscape Neurology news, join us on Facebook and Twitter.

Read the rest here:
Intracranial Atherosclerosis Not Linked to Amyloid - Medscape

Dr. Lisak honored with Healthcare Professional Champion Award for efforts against MS – The South End

Wayne State University School of Medicine Professor of Neurology Robert Lisak, M.D., FRCP, FAAN, received the Healthcare Professional Champion Award from the Michigan Chapter of the National Multiple Sclerosis Society.

The award is presented to an individual who has demonstrated their commitment to helping people meet the challenges of Multiple Sclerosis, including improving access to and quality of MS clinical care. Recipients must have demonstrated leadership in establishing relationships with other health care providers and professional organizations, increasing referrals to the society and improving MS knowledge in the health care workforce.

It is nice to be recognized for doing things that you enjoy doing for others, said Dr. Lisak, who received the honor Jan. 11 at the chapters annual Breakthroughs in MS meeting in Novi. Mich.

Mirela Cerghet, M.D., Ph.D., a neurologist with the Henry Ford Health System, presented Dr. Lisak, also a professor of Biochemistry, Microbiology and Immunology, and former chair of WSU Neurology, with the award on behalf of the chapter.

Dr. Lisak, said Dr. Cerghet, has been a champion for patients living with MS for the entire span of his distinguished career. His involvement with the National MS Society spans decades, and over the years of his service great strides have been made toward creating a world free of MS, including the development of all the disease-modifying medications.

A member of the societys Board of Trustees and chair of the Healthcare Provider Council, Dr. Lisak has played a critical role in attracting new talent to the field through his involvement in MS professional education, medical student mentoring, clinical training programs and engagement with clinical fellows, Dr. Cerghet said.

Most recently, Dr. Lisak, representing both WSU and the Consortium of Multiple Sclerosis Centers in his role on the AAN Guideline Development, Dissemination and Implementation Subcommittee, helped develop new guidelines for disease-modifying therapy for multiple sclerosis. The Consortium of Multiple Sclerosis Centers is a professional organization of MS centers and health care providers and researchers in the United States and Canada committed to a comprehensive multidisciplinary approach to treatment and care, education and research and advocacy for MS so that the centers can provide the best care and outcomes for patients and their families. The consortium also is an international clearinghouse for research results, the latest treatments, clinical trials and patient education programs.

See the rest here:
Dr. Lisak honored with Healthcare Professional Champion Award for efforts against MS - The South End

Sarepta CEO dispels FDA ‘bias’ theory, but no update on when CRL will be resolved – FierceBiotech

Sarepta Therapeutics' chief Doug Ingram has come out against accusations that the FDA is biased against the company after its recent drug rejection but offered no timing on when the agency's concerns will be fixed.

Despite not being directly mentioned in its third-quarter press release Thursday night, Ingram did address the FDAs complete response letter (CRL) to its second Duchenne muscular dystrophy (DMD) hopeful golodirsen right off the bat in his call to analysts and journalists.

He said: I must also acknowledge what we all know, that we had a setback in the third quarter. And rather than baring it among or after a discussion of our successes, I will begin by commenting our CRL disappointment that occurred in August.

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Having worked diligently on our submission for VYONDYS 53, the generic name for golodirsen for well over a year, and based on all of our interactions with the division of neurology products, we were very confident that we would obtain an approval on our PDUFA date, which was August 19.

Instead, as you know we were surprised to have received a complete response letter, also known as the CRL, signed by the Office of Drug Evaluation I. Our disappointed extends beyond Sarepta to the 8% of exon 53 amenable DMD patients in the United States to generate every day, while they await access to this therapy.

Ingram said that the biotech will now work with the agency to address the reasons for the CRL and to turn in a pathway for a potential approval, if one is possible, but offered no prediction on outcome or on timing, or to provide interim views during the process.

However, I will provide an update to the patient, physician and investment communities, once we have definitive clarity on the outcome of those discussions.

RELATED: Sarepta's Golodirsen snub highlights 'atypical communications,' heralds higher bar at FDA: analysts

The FDA rejected the New Drug Application for golodirsen, the follow-up to Exondys 51, Sareptas first treatment for DMD, in the summer over worries over the risk of infection linked to intravenous infusion portsdevices placed just under the skin to give doctors access to a veinand kidney toxicity seen in animal studies.

Like Exondys 51, golodirsen is designed to treat a group of Duchenne patients with a certain type of mutation. Exondys 51 works for about 13% of DMD patientsthose whose disease is amenable to exon 51 skipping. If approved, golodirsen would offer treatment to patients with a mutation in exon 53about 8% of the DMD population.

Sarepta has a bullish following from a vocal set of investors, who have raised concerns that the FDA may have rejected this drug because of the questionable approval it got for its first DMD drug, Exondys 51, back in 2016.

There was a lot of hand-wringing from the FDA internally about whether this met the clinical parameters needed for a regulatory green light, and some believe the CRL for Vyondys 53 has come as payback" for Exondys 51.

Ingram rejected the idea: To those may believe that the CRL suggest some sort of bias on behalf of the division of neurology towards Sarepta, I would unequivocally and emphatically disagree. Let me reiterate that I remain convinced that we were treated very fairly and professionally by the division of neurology.

He added that the CRL does have implications beyond Vyondys 53, notably for its next planned submission for PMO casimersen. As they are closely related, we will await clarity on the Vyondys matter before we submit for casimersen in the United States. But let me disabuse anyone who might have concerns.

He added, however, that the CRL does not have any read through to our microdystrophin gene therapy program. The CRL involved two safety signals in connection with an application for accelerated approval. Our microdystrophin program is overseen by a different part of the FDA, Sedar, and we are not seeking accelerated approval there. There is simply no overlap in either substance or personnel.

In a nod to the vocal investors, he also said that the noises around applying external pressure to bring this therapy a lot faster onto the market will not be coming from him.

I have no intention of doing either of those things, he said. If we can win the day with this therapy and with this issue, we will have done so on the size and on the regulation and in collaborative evidence-based discussions with our reviewers at the FDA.

Sarepta dipped slightly in the red by 0.2% after hours last night.

Visit link:
Sarepta CEO dispels FDA 'bias' theory, but no update on when CRL will be resolved - FierceBiotech

Southeastern Multi-Specialty and Urgent Care Whitevilles open house/ribbon cutting set for Friday – The Robesonian

November 09, 2019

In preparation for my recent trip to Ireland, I made sure I had my annual flu shot since I knew I would be in close quarters on the flight overseas. I very rarely get sick but figured I should error on the side of caution. Despite the flu shot, a combination of airplane air, change of climate, and one of my travel mates bringing her crud along for the trip, I ended up with some kind of chest cold.

Since my return I have tried just about everything to ditch this crud, from riding my Harley Davidson Softail really fast in order to blow the germs away, to sweating it out at CrossFit. I am happy to report that nearly two weeks later I can almost sleep through the night without coughing.

Cold season, unlike flu season, is really a 12-month affair. Anytime you get lots of people together in a space airplane, mall, movie theater, etc. chances are some of them have a cold and the germs are just waiting to jump on you.

Colds are the result of a viral infection, and there are several different types. The one that usually causes a cold in grown-ups like us is called the coronavirus and happens most often in early spring and winter. Colds cause sneezing, coughing, stuffy or runny nose and sometimes fever and chills. For the most part, colds will work their way out in three to five days, but some of the effects may linger longer.

If you are wondering about how colds affect our fitness routine, you are in the right place. Lets look at three questions regarding colds and fitness:

Does exercise prevent colds?

Regular exercise appears to have the advantage of being able to jump-start the immune system, and that can help reduce the number of colds you get. With exercise, the number and aggressiveness of certain immune cells, such as the ones called natural killer cells, increase by as much as 50% to 300%. If you exercise regularly, this temporary increase can help make the immune system more efficient at destroying intruders that cause illness such as colds. In one study reported in the American Journal of Medicine, women who walked for a half-hour every day for one year had half the number of colds as women who did not exercise. In this study, researchers associated regular walking with increasing levels of infection-fighting.

Does too much exercise make you catch a cold?

While for most of us over-exercising is not an issue, for some elite athletes it can be. Research indicates that athletes that participate in high-intensity sports marathon running, triathlons, etc. can actually get more colds. When an athlete trains too hard, the very white blood cells that help prevent illness decrease, leaving the body more vulnerable to getting sick. These ultra-athletes need to be aware and make sure they build in recovery days to their workouts to prevent illness.

Can you exercise with a cold?

Because exercise may help to boost immune function, its usually safe to exercise with a cold as long as you listen to your body. Sometimes cold medications, such as decongestants, can increase your heart rate. In addition, your heart rate is increased with exercise. The combination of exercise and decongestants can cause your heart to pump very hard. You may become short of breath and have difficulty breathing.

If you have a fever with a cold, exercise may stress your body even more. Thats why its important to wait a few days to get back to your regular exercise regimen. Working out too hard with a cold could stress your body, causing you to feel worse. This additional stress may hinder your recovery. It is best to back your exercise down a notch until you are 100%. Consult with your health-care provider if you have any questions or concerns about exercising while you are under the weather.

So there you have it. Exercise to prevent colds, keep exercising a little when you are under the weather, and dont work out so hard that your immune system crashes. My advice is to keep the hand sanitizer handy, dont drink behind your family or friends, and stay out of crowds until the sniffling season passes.

Go here to read the rest:
Southeastern Multi-Specialty and Urgent Care Whitevilles open house/ribbon cutting set for Friday - The Robesonian

Floyd Medical Center Partners With Erlanger Health System To Offer Telemedicine Technology In Neurology And Stroke Care – The Chattanoogan

Residents in northwest Georgia can now receive neurology and stroke diagnosis closer to home through a telemedicine partnership between Floyd Medical Center and Erlanger Health System.

We are pleased to work with Erlanger Health System to offer our patients tele-neurology care, said Kurt Stuenkel, president and CEO of Floyd Medical Center. This collaboration will enhance the immediate excellent care our award-winning Primary Stroke Center already provides.

"This innovative new program will improve access to specialty trained stroke neurologists to consult and diagnose, reducing the time for lifesaving treatment for patients suffering from stroke," officials said. "By offering access to neurology specialists through telemedicine, some patients may even have the opportunity to receive stroke treatment closer to home rather than transferring to another medical facility."

This tele-neurology collaboration highlights our shared commitment with Floyd to provide excellent care to those suffering from an acute neurological emergency, such as stroke, said Matthew Shafer, Erlangers administrative director of telemedicine. Tele-medicine has proven time and time again to be a powerful tool in expanding lifesaving specialty care throughout a larger region.

Officials said, "Stroke is the fifth leading cause of death and the leading cause of disability in the United States. It affects patients of all ages. The disease happens when a blood vessel carrying blood and oxygen to the brain is blocked or ruptures, decreasing the amount of blood flow to the brain cells. Risk factors for stroke disease can include high blood pressure, diabetes, heart disease, high cholesterol, obesity, smoking, family history of stroke and prior stroke or transient ischemic attack.

"In order to receive faster diagnosis and medical treatment, people must first recognize the signs of stroke and act F.A.S.T.:

Face: Ask the person to smile. Does one side of the face droop?; Arms: Ask the person to raise both arms. Does one arm drift downward?; Speech: Ask the person to repeat a simple phrase. Is her speech slurred or strange?; and Time: If you observe any of these signs, call 911 immediately."Floyd has Advanced Certification for its Primary Stroke Center from The Joint Commission. The certification recognizes centers that have the critical elements to achieve long-term success in improving outcomes for stroke patients.

"Additionally, the American Heart Association/American Stroke Association has honored Floyd with its Get with the Guidelines - Stroke GOLD PLUS Recognition. Hospitals receiving this award have reached an aggressive goal of treating stroke patients with 85 percent or higher compliance to core standard levels of care as outlined by the American Heart Association/American Stroke Association for 12 months. In addition, those hospitals have demonstrated 75 percent compliance to seven out of 10 stroke quality measures during the 12-month period."

Excerpt from:
Floyd Medical Center Partners With Erlanger Health System To Offer Telemedicine Technology In Neurology And Stroke Care - The Chattanoogan

Neurology | Baltimore | University of Maryland Medical Center

Neurology Expertise. Compassionate Care.

At the University of Maryland Medical Center, our neurology experts do more than evaluate and treat issues related to the central nervous system. Our team understands the impact of your condition on your life and helps you manage it with an individualized treatment plan.

Nationally recognized as pioneers in their fields, our neurologists work with all types ofneurological conditionsand conduct groundbreaking neurology research.

Our neurologists work closely with UMMCneurosurgeonsto provide our patients with the latest surgical procedures. For more severe-response situations, our Neurocritical Care Unit provides timely care.

As a leader in stroke care for the state and surrounding areas, our Comprehensive Stroke Center offers patients and health providers 24/7 access to stroke physicians for questions and care.

Nerve pain can be debilitating. At the University of Maryland Medical Center, our specialists provide comprehensive care for conditions related to spinal and peripheral nerves and for all types of neuropathy.

Headaches and migraines can have a big impact on your life. Pinpointing their cause and best treatment takes a headache expert. We see patients with all types of headaches, including migraine, tension and cluster headaches.

Our Parkinsons disease program offers diagnostic, medical, surgical and rehabilitative services for patients with Parkinson's disease and other movement disorders.

At UMMC, our multiple sclerosis team works closely with patients, families and primary care physicians to help patients manage their conditions effectively so they can lead active, productive lives.

As a Level 4 Epilepsy Center, UMMC hasprofessional expertise and facilities to provide the highest level of care for patients with the most complex epilepsy. Our physicians can offer comprehensive evaluation, including EEG monitoring, as they work with you to create a treatment plan for your seizures.

Call 410-328-4323 to make an appointment with one of our neurology specialists. Need a second opinion? We can help you with that, too.

See the article here:
Neurology | Baltimore | University of Maryland Medical Center

Neurologists in St. Louis | Wash U Physicians

Washington University Neurologists strive to provide outstanding clinical care and train the leading neurological doctors and scientists of the future. Our neurologists are international leaders in clinical and basic research on the disorders of the nervous system. Our goal is to bring scientific research and discovery from the bench to the bedside to improve the lives of our patients.

Each of our neurologists provide outstanding clinical care for patients of all ages, and a wide range of conditions, disorders, and diseases. While it is never easy to have a loved one dealing with any medical issue, we are here to put you at ease knowing we can provide compassionate care.

Our neurologist team offers the best in specialized procedures including:

Our PET scanner is an innovative brain imaging technique invented and developed at Washington University, and used in the neurology intensive care unit at Barnes-Jewish Hospital. The unit is one of the largest and most sophisticated in the United States.

Visit the department of neurology to learn more about a variety of conditions and to find a St. Louis neurologist near you.

For appointments, call:

AIDS Neurology - (314) 747-8423EEG Video Monitoring - (314) 362-7174Electromyography Studies (EMG) - (314) 362-3324Epilepsy - (314) 362-7845 General Adult Neurology - (314) 362-7241Memory Diagnostic Center - (314) 286-1967Multiple Sclerosis - (314) 362-3293Neuromuscular Disorders - (314) 362-6981Neurologic Rehabilitation - (314) 362-4503Pediatric Neurology - (314) 454-6120Sleep Medicine Center - (314) 362-4342Stroke - (314) 362-7382

The rest is here:
Neurologists in St. Louis | Wash U Physicians

Dr. Ruben Cintron Jr, MD – Reston, VA – Neurology …

Peripheral Nerve Disorders includes other areas of care:

- Acute Inflammatory Demyelinating Polyradiculoneuropathy

- Alcoholic Neuropathy

- Alcoholic Polyneuropathy

- Anterior Ischemic Optic Neuropathy

- Auditory Neuropathy

- Autonomic Disorders

- Autonomic Dysreflexia

- Autonomic Neuropathy

- Carcinomatous Polyneuropathy

- Carotid Sinus Syncope

- Chronic Demyelinating Neuropathy With IgM Monoclonal Gammapathy

- Chronic Inflammatory Demyelinating Polyneuropathy

- Chronic Inflammatory Demyelinating Polyradiculoneuropathy

- Congenital Neuropathy With Arthrogryposis Multiplex Congenita

- Congenital Sensory Neuropathy With Neurotrophic Keratitis

- Demyelinating Polyneuropathy

- Diabetic Neuropathy

- Diabetic Polyneuropathy

- Hand Neuropathy

- Hereditary Neuropathy With Liability to Pressure Palsies

- Hereditary Sensory and Autonomic Neuropathy, Type I

- Infantile Refsum Disease

- Inflammatory and Toxic Neuropathy

- Inflammatory Neuropathies

- Leber Hereditary Optic Neuropathy

- Metabolic Neuropathy

- Motor and Sensory Neuropathy With Sensorineural Hearing Loss, Bouldin Type

- Motor Neuropathy

- Motor Neuropathy, Peripheral With Dysautonomia

- Multifocal Motor Neuropathy

- Multifocal Motor Neuropathy With Conduction Block

- Neuropathy, Distal Hereditary Motor

- Neuropathy, Distal Hereditary Motor, Jerash Type

- Neuropathy, Distal Hereditary Motor, Type III

- Neuropathy, Distal Hereditary Motor, Type VIIa

- Neuropathy, Hereditary Motor and Sensory, Lom Type

- Neuropathy, Hereditary Motor and Sensory, Okinawa Type

- Neuropathy, Hereditary Sensory, Radicular

- Neuropathy, Hereditary Sensory, Type I

- Neuropathy, Hereditary Sensory, Type II

- Neuropathy, Hereditary Sensory, Type IV

- Neuropathy, Motor & Sensory

- Optic Neuropathy

- Peripheral Neuropathy

- Peroneal Muscular Atrophy

- Polyneuropathy

- Polyradiculoneuropathy

- Pudenal Neuropathy

- Reflex Sympathetic Dystrophy

- Retrobulbar Neuropathy

- Sensory Neuropathy With Spastic Paraplegia

- Spinal Bulbar Motor Neuropathy

- Spinocerebellar Ataxia With Axonal Neuropathy, Type 2

- Spinocerebellar Ataxia, Autosomal Recessive, With Axonal Neuropathy

- Toxic Polyneuropathy Due to Acrylamide

- Ulnar Neuropathy

- Vascular Neuropathy

See the article here:
Dr. Ruben Cintron Jr, MD - Reston, VA - Neurology ...

Neurology – University of Vermont Medical Center …

At The University of Vermont Medical Center in Burlington, VT, our University of Vermont Medical Group neurology doctors and specialists offer comprehensive, compassionate care for patients with neurological disorders and diseases - conditions affecting the nervous system including the brain, spinal cord and nerves.

Our multidisciplinary neurology team, comprised of neurologists, registered nurses and nurse practitioners, social workers and technologists, is specially trained to diagnose, evaluate and treat all types of neurological conditions in children and adults. Specialties include:

Across our services, we work collaboratively with specialists in neurosurgery, neuroradiology and neuropsychology, bringing together the expertise of multiple disciplines, centered on the needs of each patient.

Because we're a university hospital, you and your family have access to new and emerging treatments and technologies, and the latest scientific knowledge in neurology.

Our expert Neurology team is specially trained to diagnose, evaluate and treat all types of neurological problems in children and adults. The team includes:

Throughout all our services, we work collaboratively with specialists in neurosurgery, neuroradiology and neuropsychology, bringing together the expertise of multiple disciplines, centered on the needs of each patient.

Excerpt from:
Neurology - University of Vermont Medical Center ...

Pregnancy Linked to Later Onset of Progressive MS – Medscape

WEST PALM BEACH, Florida Women who have no history of a full-term pregnancy show an earlier onset of progressive multiple sclerosis (MS) compared with those who have had pregnancies, and the apparent onset-delaying effect appears to increase with the number of pregnancies, new research suggests.

The results add to speculation on the effects of pregnancy in MS.

"Our results suggest that a higher number of full-term pregnancies than average is associated with later onset of progressive MS, while having no full-term pregnancies is associated with significantly younger age at progressive MS onset," first author Burcu Zeydan, MD, an assistant professor of radiology in the Center for MS and Autoimmune Neurology at the Mayo Clinic in Rochester, Minnesota, told Medscape Medical News.

The study was presented here at the 5th annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2020.

The findings, which also link early menopause with faster disease progression, offer important insights into the broader effects of pregnancy on MS, commented ACTRIMS president Jeffrey A. Cohen, MD, who is the director of Experimental Therapeutics at the Mellen Center for MS Treatment and Research, Cleveland Clinic, Ohio.

"We know pregnancy affects the short term disease activity relapses tend to quiet down during pregnancy but what has been somewhat conflicting is whether it affects the long-term prognosis or is just a temporary effect," he told Medscape Medical News.

"So that is the main interest in this study, and it does indicate that pregnancy affects the long-term prognosis and provides some insight into the mechanism by which it might do that."

While being female is in fact considered the most important risk factor for MS susceptibility, pregnancy has been suggested to have a protective role in disease progression. However, more research is needed on the nature of the effect and its mechanisms.

For this study, Zeydan and colleagues evaluated data on 202 patients (134 women, 68 men) with MS who were part of a Mayo Clinic survey.

They found that women who had no full-term pregnancies (n = 32), had an earlier onset of progressive MS (mean age 41.4 12.6 years) compared with women giving birth to one or more children (n = 95; 47.1 9.7 years; P = .012).

In addition, the mean age of progressive MS onset increased with a dose-effect trend according to the number of full pregnancies (no children, 41.4 12.6 years; 1-3 children: 46.4 9.2 years; 4 or more children: 52.6 12.9 years; P = .002).

A look at a subgroup of patients with secondary progressive MS also showed an earlier mean age of onset among women who had no full pregnancies(n = 19; 41.5 9.2 years) compared with women who had one or more full pregnancies (n = 57; 47.3 10.6 years; P = .049).

The later disease onset associated with pregnancy was also seen in relapsing-remitting MS: Mean age of onset was earlier women with no pregnancies (27.5 7.0 years) compared with those with one or more children (33.0 9.4 years;P = .021).

The mean duration of time from relapsing-remitting MS to secondary progressive MS was also shorter among women with premature or early menopause (n = 26; 12.9 9.0 years) compared with those who had menopause at a normal age (n = 39; 17.8 10.3 years).

The pattern was similar for women experiencing the onset of secondary progressive MS after menopause, with a shorter progression among those with early menopause (P = .012).

The trends of later onset with more pregnancies was also observed with the mean age of onset of secondary progressive MS (no full pregnancies: onset at 41.5 9.2 years; 1-3 pregnancies: onset 46.2 9.9 years; 4 or more pregnancies: onset 52.6 12.9 years; P = .010).

And likewise, the later mean age of onset of relapsing-remitting MS was seen with additional pregnancies (no full pregnancies: 27.5 7.0 years; 1-3 pregnancies: 32.4 9.3 years; 4 or more pregnancies: 35.8 9.8 years;P = .012).

"The dose effect was clearly a surprise (having no full-term pregnancies vs 1-3 vs 4 or more)," Zeydan said.

"In addition to the significant difference between having no vs 1 or more full-term pregnancies, the clear dose-effect consolidates our results related to the association between the number of pregnancies and age at progressive MS onset."

The study also showed that women with premature or early menopause had a shorter duration of progression from relapsing-remitting MS to secondary progressive MS (n = 26; 12.9 9.0 years) compared with women who experienced menopause at a normal age (n = 39; 17.8 10.3 years).

The patterns in early menopause are consistent with previous observations regarding menopause and MS progression, Cohen said.

"When women go through menopause, estradiol and pregnancy-related factors further decline and we know this coincides temporally with the development of progressive MS in women," he noted.

Compared with men, women with premature or early menopause furthermore had a longer duration from relapsing-remitting MS to secondary progressive MS (P = .008), and women with secondary progressive MS also had also had an earlier age of relapsing-remitting MS onset than men (P = .018).

The mechanisms of pregnancy could include a complex interaction between estrogen and factors such as astrocyte and microglia function, Zeydan explained.

"Estrogen, through various mechanisms of eliminating toxicity of highly activated neurons including preventing pro-inflammatory molecule release, supporting mitochondria function thereby eliminating energy failure, and promoting remyelination helps neuronal plasticity and delays neurodegeneration, which is closely related to the progressive phase of MS," she said.

"One could easily make the probable association, while yet to be proven, that our findings may relate to these mechanisms," Zeydan said.

The logical question of whether hormone replacement or some type of therapy that could mimic the effects of pregnancy could also benefit in delaying MS onset remain to be seen, Zeydan said.

"While we believe that is possible, particularly for delaying the onset of progressive phase, definitive evidence is lacking at this time," Zeydan said. "However, our study ultimately may lead to such a trial."

In the meantime, the findings provide additional insights that may be beneficial in sharing with patients regarding pregnancy, she said.

"As the contemporary problem in MS care is to delay or prevent progressive MS onset, our findings may suggest that how we counsel women with MS who are planning to get pregnant, or contemplating surgically induced menopause, or how we consider hormone therapies during perimenopause, may impact the course of their disease."

Zeydan cautions, however, that "our findings do not confirm causality beyond an association."

"More studies are needed in this important issue in a disease that affects women three times more than men," she stressed.

Zeydan has disclosed no relevant financial relationships. Cohen reports personal compensation for consulting for Adamas, Convelo, MedDay, Mylan, and Population Council; and serving as an editor of Multiple Sclerosis Journal.

Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2020: Abstract P135. Presented February 27, 2020.

For more Medscape Neurology news, join us on Facebook and Twitter

Read this article:
Pregnancy Linked to Later Onset of Progressive MS - Medscape

Natalizumab Linked to Disability Improvement in Early Relapsing-Remitting MS – Neurology Advisor

WEST PALM BEACH, FL More patients with early relapsing-remitting multiple sclerosis (RRMS) treated with natalizumab experienced confirmed disability improvement than confirmed disability worsening, with the majority of improvement occurring in the first year and most patients maintaining confirmed disability improvement through the end of a 4-year study, according to research presented at the 5th annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2020, held February 27-29 in West Palm Beach, Florida.

This 4-year, multicenter, observational, open-label, single-arm study of patients initiating natalizumab therapy <3 years postdiagnosis of RRMS (STRIVE), was designed to evaluate disability improvement over 4 years of treatment. Confirmed disability improvement was defined as a >1.0 decrease in Expanded Disability Status Scale (EDSS) score from a baseline score >2.0, confirmed after 24 weeks. Confirmed disability worsening was defined as a >0.5 increase in EDSS from a baseline score > 6.0, or a >1.0 increase from a baseline score of 1.0 to 5.5, or a >1.5 from a baseline score of 0.0, confirmed after 24 weeks.

Cumulative confirmed disability improvement or disability worsening probabilities were assessed with Kaplan-Meier methods. Confirmed disability improvement maintenance was defined by a continued EDSS reduction by >1 point. A multivariate spline-based accelerated failure time model was used to evaluate baseline characteristics (age, multiple sclerosis disease duration, EDSS score, T2 lesion volume, number of gadolinium-enhancing lesions, and relapses in the prior year) as confirmed disability improvement predictors.

A total of 222 participants were included in the intent-to-treat population, of whom 133 had a baseline EDSS score of >2.0. During the 4-year study, 32.3% of participants with such an EDSS score experienced confirmed disability improvement; 62.8% had an EDSS score reduction of >1.5, and 44.2% had a reduction of >2.0 points. The cumulative probability of confirmed disability improvement was 19.9% at 1 year, 28.4% at 2 years, 38.5% at 3 years, and 43.9% at 4 years.

Among those with confirmed disability improvement, 62.8% maintained improvement through all 4 years of the study. No baseline characteristics were found to be confirmed disability improvement predictors, and the cumulative confirmed disability worsening probability at 4 years was 19.3%.

The investigators concluded, In this analysis of patients treated with natalizumab in STRIVE, more patients experienced [confirmed disability improvement] than CDW. [Confirmed disability improvement] occurred during each year of the study with most improvement taking place in the first yearThese results are consistent with findings from other real-world studies and support the effectiveness of natalizumab in patients with early RRMS.

Visit Neurology Advisors conference section for continuous coverage from the ACTRIMS 2020 Forum.

Reference

Perumal J, Fox R, Balabanov R, et al. Disability improvement in early multiple sclerosis patients treated with natalizumab in STRIVE, a phase 4 multicenter observational study. Presented at: ACTRIMS Forum 2020; February 27-29, 2020; West Palm Beach, FL. Abstract P056.

Read more:
Natalizumab Linked to Disability Improvement in Early Relapsing-Remitting MS - Neurology Advisor

Effect of Galcanezumab on Cardiovascular Outcomes in Adults With Migraine – Neurology Advisor

Treatment with galcanezumab in patients with episodic and chronic migraine does not result in changes in hemodynamic parameters or increase the risk of cardiovascular (CV) events, according to study results published in Headache.

Galcanezumab, a humanized IgG4 monoclonal antibody that binds calcitonin gene-related peptide, is approved for the preventive treatment of migraine in adults. Because the CV effects of galcanezumab are not clear, the researchers assessed the effect of galcanezumab, compared with placebo, on blood pressure, changes in electrocardiograms, and CV events in patients with episodic or chronic migraine.

The researchers used data from 3 phase 3, double-blind, placebo-controlled studies of patients aged 18-65 years: 2 similar 6-month studies that included patients with episodic migraine (EVOLVE-1 and EVOLVE-2) and a single 3-month study of patients with chronic migraine (REGAIN). The subjects were randomized (1:1:2) to monthly subcutaneous injections of galcanezumab 120 mg, galcanezumab 240 mg, or placebo.

Treatment comparisons for CV treatment-emergent adverse events (TEAEs), and categorical and mean changes in blood pressure, pulse, and electrocardiograms were evaluated.

A total of 705 patients were treated with galcanezumab 120 mg, 730 patients were treated with galcanezumab 240 mg, and 1451 patients were in the placebo group. Of the 2886 adults included in the analysis, 1773 patients had episodic migraine and 1113 had chronic migraine.

The frequency of at least 1 CV TEAE was 2.6% (18 cases) for galcanezumab 120 mg, 3.3% (24 cases) for galcanezumab 240 mg, and 2.9% (42 cases) for placebo, with no significant differences between the groups (galcanezumab 120 mg vs placebo: odds ratio 0.9; 95% CI, 0.5-1.5; galcanezumab 240 mg vs placebo: odds ratio 1.1; 95% CI, 0.7-1.9).

Researchers noted there were no likely CV TEAEs documented in the 8 galcanezumab-treated patients with a history of ischemic central nervous system vascular conditions, cardiomyopathy, or cardiac failure.

Serious CV adverse events were documented in 3 patients (0.4%) treated with galcanezumab 240 mg (pulmonary embolism, myocardial infarction, and transient ischemic attack) and in 3 (0.2%) placebo-treated patients (pulmonary embolism, deep vein thrombosis, and myocardial infarction), whereas in the group of patients treated with galcanezumab 120 mg, there were no serious events.

Compared with placebo, galcanezumab treatment for up to 6 months did not lead to mean increases in blood pressure or pulse. Overall, the percentage of patients with increases in blood pressure or pulse were similar among patients treated with galcanezumab compared with those receiving placebo.

The researchers noted the study had several limitations, including short treatment duration, low frequency of CV events, and exclusion of patients with acute or serious CV risk or serious medical conditions.

The data from this integrated analysis do not suggest that galcanezumab treatment in patients with migraine resulted in hemodynamic changes consistent with vasoconstriction or an increase in CV [cardiovascular] adverse events, including those related to ischemia up to 6 months of treatment, concluded the researchers.

Disclosure: This clinical trial was supported by Eli Lilly and Company. Please see the original reference for a full list of authors disclosures

Reference

Oakes TM, Kovacs R, Rosen N, et al. Evaluation of cardiovascular outcomes in adult patients with episodic or chronic migraine treated with galcanezumab: data from three phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies. [published online ahead of print, 2019 Nov 13]. Headache. 2019;10.1111/head.13684. doi:10.1111/head.13684

Link:
Effect of Galcanezumab on Cardiovascular Outcomes in Adults With Migraine - Neurology Advisor

Blood Pressure Key to Good Outcomes in Stroke Thrombectomy – Medscape

Both low and high levels of blood pressure during endovascular treatment of acute ischemic stroke are associated with poor functional outcome, a new study suggests.

"Our study has very clinically relevant findings that best outcomes are achieved if the mean arterial blood pressure [MABP] is kept between 70-90 mm Hg," lead author, Mads Rasmussen, MD, PhD, Aarhus University Hospital, Denmark, told Medscape Medical News.

"Our main message is that strict blood pressure protocols are needed during endovascular therapy for stroke," Rasmussen said. "We need be meticulous about blood pressure management during this procedure as patients are very sensitive to blood pressure changes. If we do not manage blood pressure well during the procedure, then this can have a meaningful adverse impact on outcomes."

The study was published online in JAMA Neurology on January 27.

It's known that blood pressure drops transiently during the endovascular procedure and previous studies have suggested that low blood pressure adversely affects outcomes, "but we haven't known what the blood pressure threshold is and for how long it can go below this threshold," Rasmussen explained.

"This is what we set out to look at in this study," he said. "We also wanted to see if there was an upper threshold for blood pressure related to outcomes."

For the current study, the researchers analyzed data from three randomized controlled trials in a total of 380 patents investigating anesthetic strategy during endovascular treatment for stroke.

"One of the main strengths of our analysis is that all the three studies we used had strict blood pressure protocols in place. This has not been the case in previous studies that have tried to investigate the effect of blood pressure on outcomes," Rasmussen noted.

Results showed that a cumulated period of a minimum 10 minutes with less than 70 mm Hg MABP was associated with a shift toward a higher 90-day modified Rankin scale (mRS) score (adjusted odds ratio [OR], 1.51; 95% confidence interval [CI], 1.02 - 2.22) and a number needed to treat to harm 1 patient of 10.

A continuous episode of a minimum 20 minutes with less than 70 mm Hg MABP had a higher risk of an increased 90-day mRS score (adjusted OR, 2.30), corresponding to a number needed to treat to harm 1 patient of 4.

At the other end of the spectrum, a cumulated period of a minimum 45 minutes with greater than 90 mm Hg MABP was associated with a shift toward a higher 90-day mRS score (adjusted OR, 1.49), corresponding to a number need to harm of 10.

And a continuous episode of a minimum 115 minutes with greater than 90 mm Hg MABP showed a greater risk of a higher mRS score (adjusted OR, 1.89), corresponding to a number needed to harm of 6.

"These results suggest These results suggest MABP may be a modifiable therapeutic target to prevent or reduce poor functional outcome in patients undergoing [endovascular treatment] for [acute ischemic stroke] and that MABP should possibly be maintained within such narrow limits," the authors conclude.

"I would say though, that from our data, mean arterial blood pressure should be kept between 70 and 90 mm Hg. There are bound to be the occasional drops below 70 mm Hg, but these should be kept to a minimum if possible," Rasmussen commented.

"This is the best data we have so far on optimum blood pressure levels during endovascular treatment for stroke, but it still needs confirmation if possible in a randomized trial," he added.

Rasmussen noted that this is the first study to have shown that higher levels of blood pressure may also lead to poor outcomes during endovascular treatment, although the relationship is much weaker than that for low blood pressure.

"Our results confirm that the previously established U-shaped blood pressure pattern is also relevant in stroke patients undergoing endovascular treatment," he stated.

"We used mean arterial blood pressure. Other studies have used systolic blood pressure, and some have suggested that this should kept above 140 mm Hg. Mean arterial blood pressure takes into consideration both systolic and diastolic levels. Further studies are needed to give information on which measurement is best," he added.

In the paper, the authors say their findings suggest that MABP is more sensitive than systolic pressure in the assessment of hypertension and hypotension.

"Cerebral perfusion pressure, defined as the difference between MABP and intracranial pressure, is considered the physiologic driving force behind cerebral blood flow. Furthermore, MABP is a combination of systolic and diastolic blood pressures and is considered a more valid index of tissue perfusion," they write.

"We hypothesize that a MABP threshold is a more appropriate indicator of hypertension and hypotension during [endovascular treatment] for [acute ischemic stroke]," they conclude.

Rasmussen was supported by a grant from the Health Research Foundation of Central Denmark Region and the National Helicopter Emergency Medical Service Foundation, Denmark. The remaining study authors' disclosures are listed in the paper.

JAMA Neurol. Published online January 27, 2020. Abstract

For more Medscape Neurology news, join us on Facebook and Twitter.

Here is the original post:
Blood Pressure Key to Good Outcomes in Stroke Thrombectomy - Medscape

Caffeine helping to treat young patients in Sydney with neurological disorders – 7NEWS.com.au

Sydneys Childrens Hospital at Westmead has stumbled upon a remarkable treatment for a group of young patients with a rare neurological disorder.

Its easy to source, perfectly safe and cheap. In fact, most of us already consume it every day in our cup of coffee.

Put simply its caffeine - and its helping patients like four-year-old Grace Maly.

At around four-months-old, a virus lead to a sudden change in Graces development.

Her mother Emma describes how she went floppy.

Emma says, We knew something wasnt right because she couldnt sit up. She wasnt reaching her milestones.

At first, it was a mystery but after years of searching, Grace was diagnosed with a mutation in the ADCY5 gene. A movement disorder prevents her from independently sitting or standing.

Emma says, ever since life has been very different. Its been very up and down. An emotional roller coaster.

More on 7NEWS.com.au

One of hardest impacts is seizures, up to 10 times a day.

Until, the family heard about an unlikely new treatment - caffeine.

Grace takes three doses of prescription caffeine each day and her father Adam describes the results as amazing.

We knew something wasnt right because she couldnt sit up. She wasnt reaching her milestones.

Grace can now feed herself a sandwich by herself. Play Duplo with her brothers. So its really wonderful.

Other families are benefiting too under supervision at The Childrens Hospital at Westmead.

Dr Shekeeb Mohammad says this is what medical professionals dream about, It is immensely satisfying and it is thrilling to be able to see a change in our patients.

Previously, physical therapy has been the only other form of treatment.

The caffeine therapy was in fact an accidental discovery made in France.

A patient there with the condition stopped drinking his usual daily coffee and his symptoms suddenly became far worse.

Older patients like Francesca Risi have followed his lead, drinking straight espresso.

Her mother Angelina says Its amazing for us to see that something so simple can help her put her hand up in class in time to answer a question.

Francescas father Adrian says he just wants his daughter to live a happy life, It gives us probably hope that there are more and more things to be discovered.

Exactly why the caffeine works is still a mystery.

So today, on Rare Diseases Day, the families are sharing their stories, hoping for more answers and maybe one day a cure.

If youd like to help, please follow the links below:

View original post here:
Caffeine helping to treat young patients in Sydney with neurological disorders - 7NEWS.com.au

Prevalence and Risk Factors of Restless Legs Syndrome in Hemodialysis | NSS – Dove Medical Press

Li-Yan Zhang, 1,* Xiao-Yang Ma, 2,* Jun Lin, 3 Wen-Hu Liu, 4 Wang Guo, 4 Le Yin, 4 Shi-Xiang Wang, 3 Xia Li, 5 Jing Li, 5 Li-Li Jin, 6 Ze-Long Tian, 7 Yi-Tong Du, 1 Hou-Zhen Tuo 1

1Department of Neurology, Beijing Friendship Hospital, Capital Medical University, Beijing, Peoples Republic of China; 2Department of Neurology, Beijing Ditan Hospital, Capital Medical University, Beijing, Peoples Republic of China; 3Department of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing, Peoples Republic of China; 4Department of Nephrology, Beijing Friendship Hospital, Capital Medical University, Beijing, Peoples Republic of China; 5Blood Purification Center, Beijing No. 6 Hospital, Beijing, Peoples Republic of China; 6Department of Nephrology, Beijing Zhongxing Hospital, Beijing, Peoples Republic of China; 7Department of Neurology, Tianjin 4th Central Hospital, Tianjin, Peoples Republic of China

*These authors contributed equally to this work

Correspondence: Hou-Zhen TuoDepartment of Neurology, Beijing Friendship Hospital, Capital Medical University, No. 95 Yongan Road, Xicheng District, Beijing 100051, Peoples Republic of ChinaTel/Fax +86 10-63139807Email tuohzh@sina.cn

Objective: The current study aimed to investigate the prevalence and risk factors of restless legs syndrome (RLS) in patients undergoing hemodialysis, as well as the mortality and risks of cardiovascular and cerebrovascular events.Methods: A total of 354 hemodialysis patients from four hospitals were enrolled. RLS was diagnosed using the International RLS Study Group (IRLSSG) criteria. The patients were evaluated face-to-face using the IRLSSG rating scale, Epworth Sleepiness Scale (ESS), Hamilton Anxiety Scale, Hamilton Depression Scale, and Pittsburgh Sleep Quality Index (PSQI). The patients were followed up for 9 months. Death was considered an endpoint event. The cardiovascular and cerebrovascular events were investigated.Results: The prevalence of RLS in hemodialysis patients was 40.7% and was associated with factors such as duration of hemodialysis, hypersensitive C-reactive protein, hyperparathyroidism, glycosylated serum protein, and erythropoietin treatment. The scores of the PSQI, ESS, and Hamilton Depression Scale in the RLS group were significantly higher than those in the non-RLS group (p < 0.05). During follow-ups, the incidence rate of cardiovascular diseases was 18.8% in the RLS group and 8.6% in the non-RLS group (p < 0.005). The IRLSSG rating scores were significantly higher in RLS patients with kidney transplantation failure compared with those without transplantation (p < 0.05).Conclusion: The prevalence of RLS was high in hemodialysis patients. The risk factors of RLS included duration of hemodialysis, hypersensitive C-reactive protein, hyperparathyroidism, glycosylated serum protein, and erythropoietin treatment. RLS affected sleep quality and emotion and increased the risk of cardiovascular diseases in hemodialysis patients. RLS was more severe in patients with kidney transplantation failure compared with those without transplantation.

Keywords: restless legs syndrome, hemodialysis, prevalence, risk factor, cardiovascular disease

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Continue reading here:
Prevalence and Risk Factors of Restless Legs Syndrome in Hemodialysis | NSS - Dove Medical Press

Neurology Endoscopy Devices Market To 2026 Top Impacting Factors To Growth Of The Industry – Briotainment

The report titled, Neurology Endoscopy Devices Market boons an in-depth synopsis of the competitive landscape of the market globally, thus helping establishments understand the primary threats and prospects that vendors in the market are dealt with. It also incorporates thorough business profiles of some of the prime vendors in the market. The report includes vast data relating to the recent discovery and technological expansions perceived in the market, wide-ranging with an examination of the impact of these intrusions on the markets future development.

This market research report on analyzes the growth prospects for the key vendors operating in this market space including Karl StorzAesculapAdeor MedicalAckermann InstrumenteHawkRudolf MedicalRichard WolfKapalin BiosciencesMachida EndoscopeRenishawVisionsenseWanhe MedicalAn operating microscope or Neurology Endoscopy Devices is an optical microscope specifically designed to be used in a surgical setting, typically to perform microsurgery.

Request Sample Copy of this Report@: https://www.healthcareintelligencemarkets.com/request_sample.php?id=1413

Global Neurology Endoscopy Devices Market research survey represents a comprehensive presumption of the market and encloses imperative future estimations, industry-authenticated figures, and facts of market. The report portrays the keys factors affecting the market along with detailed analysis of the data collected including prominent players, dealers, and the sellers of the market.

In addition, it helps the venture capitalists in understanding the companies better and make informed decisions. The regions covered includes North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. The revenue is generated mainly from North America, Europe, and Asia Pacific. North America is leading the market followed by Europe with Asia Pacific emerging in Neurology Endoscopy Devices Market.

Get Reasonable Discount on this Premium Report @: https://www.healthcareintelligencemarkets.com/ask_for_discount.php?id=1413

Key Findings of the Global Neurology Endoscopy Devices Market:

1. What will the market size and the growth rate be in 2026?

2. What are the key factors driving the Global Neurology Endoscopy Devices Market?

3. What are the key market trends impacting the growth of the market?

4. What are the challenges to market growth?

5. Who are the key vendors in the Global Neurology Endoscopy Devices Market?

6. What are the market opportunities and threats faced by the vendors in this market?

This report provides an effective business outlook, different case studies from various top-level industry experts, business owners, and policymakers have been included to get a clear vision about business methodologies to the readers. SWOT and Porters Five model have been used for analyzing the Neurology Endoscopy Devices Market on the basis of strengths, challenges and global opportunities in front of the businesses.

For More Information: https://www.healthcareintelligencemarkets.com/enquiry_before_buying.php?id=1413*If you need anything more than these then let us know and we will prepare the report according to your requirement.About Us:At HealthCare Intelligence MarketsContact Us:Address: 90, State Office Center,90, State Street Suite 700,Albany, NY 12207Email: sales@healthcareintelligencemarkets.comWeb: http://www.healthcareintelligencemarkets.comPhone: +1 (888) 616-2766

See the article here:
Neurology Endoscopy Devices Market To 2026 Top Impacting Factors To Growth Of The Industry - Briotainment

Ground-breaking study could reveal true cause of fatal chronic wasting disease – OutThere Colorado

Chronic wasting disease is a growing threat for deer, elk, and moose in North America, infecting a larger portion of the populations each year.

The fatal disease attacks the neurological system and seems, at this point, impossible to cure. Adding another layer to this complicated issue is a recent discovery that might indicate that efforts to stop it have been misaligned, with silver-lined implications that could have dire consequences if not heeded.

Weve got to do something soonwhy do the research if the problem disappears, said Dr. Frank O. Bastian, implying that if chronic wasting disease is not stopped, it could be detrimental to entire cervid species.

Chronic wasting disease (CWD) is considered a transmissible spongiform encephalopathy, or TSE, which puts it in the same class as mad cow disease. Traditionally, always fatal TSE brain diseases have been considered to be the result of a deformed protein called a prion and studied as such. But one group of scientists led by Dr. Frank O. Bastian believes this explanation might not be accurate for CWD or other TSEs.

In an article published in the American Association of Neuropathologists Journal of Neurology and Experimental Neuropathology (November 2019), Dr. Frank O. Bastian, a neuropathologist currently with the University of New Orleans and formerly with the Louisiana State University Agricultural Center, and his team of researchers claim that CWD is caused by a spiroplasma bacterium. If thats the case, it could mean that decades spent looking for an answer in prions might be for naught.

In order to comprehend the potential impact of Bastians claim, its important to understand the difference between a bacterium and a prion.

One distinguishing factor is prions dont contain nucleic acid while bacteria do. This means attempts to destroy a disease-causing pathogen by breaking down the nucleic acid wont work on a prion.

Another crucial difference is that a prion is a deformation of a protein that already exists in the body, meaning the deformation of a native protein wont trigger an immune system response that bacterial microbes might. Keep in mind that vaccinations work because they intentionally trigger this immune response, thus training the body to recognize and fight certain pathogens.

While vaccines wont work on prion-caused conditions, they can work on a bacteria-caused disease, as is the case with typhoid. This could open the door for preventative vaccinations if CWD is bacteria-caused.

The claim that TSEs might be caused by a spiroplasma bacterium instead of a deformed prion allegedly came after Dr. Bastian was able to isolate a bacteria microbe from the tissues of TSE-infected animals, including deer with CWD. After the microbe was isolated in his laboratory setting, it was put back into healthy animals, which then developed spongiform encephalopathy. In other words, after this isolated bacterium was introduced to otherwise healthy animals, they developed symptoms characteristic of naturally occurring TSEs.

According to Bastian, this previously unidentified species of bacterium can be considered an extreme thermoacidophile thats very difficult to kill. Microorganisms found in acid mine drainages, deep sea vents and thermal hot springs often fall into this category. In order to determine this attribute, Bastian put the bacterium through several tests and it survived them all, including exposure to boiling, formaldehyde, gamma irradiation, and extreme acidity. This ability to test the unidentified bacterium due to the new ability to consistently grow the organism in a culture is something Bastian considers to be one of his greatest recent successes.

Bastian has been studying CWD for more than a decade. In 2007, he injected spiroplasma bacteria into laboratory animals, which reportedly led to the animals showing signs of CWD in less than two months. He believes that while prions might be deformed in CWD victims, these are merely a sign the disease is present, not the cause.

Despite Bastians extensive research, his claim of CWD causation is not widely supported. According to John Eveland, project director of North American CWD Project, a large majority of scientists studying the subject hold to the belief that the disease is caused by a prion despite little progress in understanding CWD or preventing its spread over several decades of research. Eveland says that the funding for CWD research reflects this division, with virtually all funding devoted to prion research.

While there arent official reports of CWD infection in humans, health organizations advise against eating infected meat and research is ongoing.

One study, started in 2009 by a group of Canadian and German scientists, is working to determine if CWD can be transmitted to macaques a type of monkey that is genetically closer to humans than any other species that has contracted CWD. While the results have yet to be published in academic literature, the scientists have publicly presented their progress, which preliminarily showed that monkeys can be infected with CWD by eating the muscle or brain tissues of infected animals. At times, this transmission is said to have occurred prior to the infected animal showing symptoms. When Bastian was asked about this study, he wasnt willing to throw his support behind the data, acknowledging that it had yet to be published.

If transmission to humans is possible, it likely would put many at risk. One 2006-2007 estimate from the Center for Disease Control and Prevention indicated that more than two-thirds of Americans have eaten cervid meat. Keep in mind that TSEs tend to have a very long incubation period in humans, up to several decades, allowing the infection to go unnoticed for years.

While the verdict is out on whether or not humans are susceptible to CWD, other diseases in the TSE classification can be contracted by humans. One condition that is similar to CWD is Creutzfeldt-Jakob disease (CJD). Like CWD, CJD traditionally has been believed to be the result of a misfolded prion and is a fatal degenerative disorder that impacts the neurological system. Unlike CWD, which tends to have an incubation period of around 16 months in deer, CJD typically has an incubation period of decades in humans, with most people that show signs of the disease aged between 60 and 65. Some worry that if CWD is infecting humans, it might have a similarly long incubation period making the disease difficult to diagnose.

In the wake of Bastians most recent research, North American CWD Project was formed to help advance his attempt to develop new diagnostic tests and vaccines related to CWD. Primary research for the project is now being conducted at the University of New Orleans Advanced Materials Research Institute in the Bastian Laboratory for Neurological Disease Research. Field tests are expected to take place at a second research facility in Pennsylvania.

The group has targeted four areas it believes could help fight the spread of CWD. First, the group hopes to address a key problem with CWD effectively determining which animals are infected. Currently, testing is a slow process that requires hunters to bring the carcass to a designated facility. North American CWD Project is pushing to develop a field diagnostic kit that will allow hunters to test the animal at the kill site. The next goal is to create a live-animal test. The group believes that better access to testing will prevent humans from ingesting potentially infected meat.

The group also aims to develop antibiotic vaccines that might prevent the spread of the disease one that would be injectable for captive animals and another that would be oral for free-range animals. One major implication of CWD being caused by a bacterium and not a prion would be that vaccines could be an effective solution. The goal is to have the vaccines created within three years.

Finally, the group is trying to develop a cure for the human-infecting Creutzfeldt-Jakob Disease within 5-6 years, moving on to address additional neurological diseases such as Alzheimers and Parkinsons within 6-10 years.

One roadblock to this plan of attack, according to project director John Eveland, is lack of funding considering that nearly all government and private money spent is spent on prion research.

Colorado Parks and Wildlife refutes the claim that CWD could be caused by a spiroplasma bacteria.

Support for their stance includes a 1982 study by Dr. Stanley Prusiner that demonstrated that the causative agent of another TSE disease was most likely protein based. This was concluded after a scrapie-infected brain remained infectious after bacteria destroying enzymes were introduced. When protein-neutralizing enzymes were introduced, the infectivity dropped.

In another 2006 study cited by Colorado Parks and Wildlife representatives (Irina Alexeeva, et al.), researchers found that no bacteria was consistently associated with scrapie, drawing the conclusion that the agent responsible for TSE disease cannot be spiroplasma or any other eubacterial species.

One study conducted by Hilari Maree French (2011) had difficulty recreating research claims that supported the bacteria-causation of CWD. During this study, French found that three spiroplasma bacteria tested were each susceptible to common laboratory disinfectants. This same research introduced spiroplasma mirum to animals with no resulting infection. The species of bacteria that Bastian claims to have identified as the cause of CWD is not spiroplasma mirum.

The Association of Fish and Wildlife Agencies also disputes claims that CWD may be caused by something other than a prion. Their official statement is as follows: We felt that until there was definitive proof otherwise, it was important that the Association go on the record as supporting the overwhelming scientific consensus that Chronic Wasting Disease is caused by mutated protein known as prions.

According to Eveland, claims that Dr. Bastians research has not successfully been duplicated are false. According to Dr. Bastian, no one has adequately tried.

While Bastains research has stoked the debate regarding what causes CWD, it seems as if official organizations are lagging when it comes to adopting findings from the study. Definitively determining the cause of CWD and garnering support from the larger scientific community will likely prove crucial in stopped the spread of this infection before its too late.

We are driven by our deep respect for our environment, and our passionate commitment to sustainable tourism and conservation. We believe in the right for everyone - from all backgrounds and cultures - to enjoy our natural world, and we believe that we must all do so responsibly. Learn More

Follow this link:
Ground-breaking study could reveal true cause of fatal chronic wasting disease - OutThere Colorado

The Many Ways of Coping With Alzheimers – The New York Times

To the Editor:

I am the neurologist with early-stage Alzheimers disease mentioned in A Test for Alzheimers Poses a Tough Choice (Science Times, Dec. 24). Testing for Alzheimers, especially in the earliest stages, is controversial, even among dementia experts. For me, though, the early diagnosis was empowering. It removed the uncertainty about the cause of my mild cognitive impairment and allowed me to concentrate on doing everything that I could to slow the progression of the disease.

The first pathological changes in the brain, the amyloid plaques, appear up to 20 years before there is any cognitive impairment. My first symptoms of Alzheimers occurred 14 years ago when I started to lose my sense of smell and began to experience illusory odors. My cognitive impairment began six or seven years ago and has slowly worsened. Still, most people would have no idea that there is anything wrong with me.

It is becoming apparent that the first effective, disease-modifying medications will likely work in the early stages, before there has been too much damage to the brain. And there is already overwhelming evidence that lifestyle modifications like aerobic exercise and a heart-healthy diet slow the accumulation of amyloid and postpone cognitive impairment if they are started in the earliest stages.

Early testing for Alzheimers disease will not be for everyone, but I dont think that it should be rejected out of hand.

Daniel GibbsPortland, Ore.

To the Editor:

Would I really want to know? is a question your article highlights, but when Alzheimers enters a familys life, another question is almost always asked: What do I do now? At the Alzheimers Foundation of America, we hear it every day.

Support services are available for affected families, but greater federal investment is needed. Washington deserves praise for delivering over $2.8 billion in Alzheimers research funding in fiscal year 2020, but funding for the Administration for Community Livings Alzheimers programs, including specialized dementia caregiver training and support, is only $26.5 million. While its an increase from fiscal year 2019, the Centers for Disease Control and Prevention estimates that the number of Americans with Alzheimers will nearly triple by 2060, from over five million now to 14 million. Given these projections, greater resources are needed.

Diagnosing a problem is critical. Addressing it once its identified is equally important. The development of new diagnostic tools makes it essential that we prioritize care and support until a cure is found.

Charles J. Fuschillo Jr.New YorkThe writer is president and chief executive of the Alzheimers Foundation of America.

To the Editor:

As an individual with a family history of Alzheimers, I understand the conflicts involved in assessing whether we want to know our risks of getting the disease. I took part in Dr. Jason Karlawishs study of patients responses to the news of amyloid levels because I wanted to be able to plan for my future.

Receiving the news that there was no amyloid in my brain provided relief beyond expression. If the results had been different, however, I would have accepted them with the knowledge that I could plan for my ultimate demise in a way that would work for me and be helpful to my loved ones.

Alan N. FrankelBryn Mawr, Pa.

To the Editor:

Happily Married for 60 Years. Then Alzheimers. And a Gun. (front page, Dec. 29) was devastating. It reinforced the reality that too few people realize there are humane and legal ways to reduce needless suffering, even for somebody with dementia.

All mentally competent adults have the right to document that they want to forgo medical treatments if they get dementia. Their designated health care proxy can then carry out their wishes, significantly shortening the time they endure the most debilitating stages of dementia.

If you are a mentally competent adult, you can create a dementia directive and attach it to your advance directive.

Kim CallinanWashingtonThe writer is president and chief executive of Compassion & Choices.

To the Editor:

I read with sadness and more than a bit of dismay the disturbing portrait of a loving husband caring for his wife afflicted with Alzheimers disease. The burdens on caregivers of people living with dementia are well documented: depression, social isolation, worsening physical health and, in some cases, resistance to accepting help.

There is much we can do to relieve this burden for such families. I wish the article had referred to the exceptional work that well-informed physicians, nurses, social workers and mental health specialists do each and every day to identify and support families that are having an especially difficult time coping with the demands of dementia caregiving.

It is tragic that this family did not benefit from more effective professional dementia support interventions, which must be made available in every community, for every family in need.

William E. ReichmanMilwaukeeThe writer, a physician, is president of the International Psychogeriatric Association.

To the Editor:

Few Americans are lucky enough to have long-term care insurance. We expect spouses to provide care at home and assume that will be enough. Then we act surprised when someone, in complete desperation, resorts to murder-suicide.

I cared for my wife, who had multiple sclerosis, for 50 years until her death. Many of those years were wonderful and productive. But when her M.S. became progressive, our health care system provided almost no long-term care at all. Care was provided by me, by home health aides who were paid privately and by some family members who were kind enough to provide relief.

The aides earned a median income of about $22,000 a year. The lowest paid people in the medical field are the ones who provide care for the chronically ill and the dying.

A support group can help. I belonged to the Well Spouse Association, a national nonprofit support group for the spouses/partners of the chronically ill or disabled. They provided meetings, respite and other services, which helped me to keep going and prevented me from becoming desperate.

Bob MastroCherry Hill, N.J.

To the Editor:

Your article doesnt point out the troubling fact that domestic violence homicides and familicides (including murder-suicides) are on the rise in the United States, despite overall declines in homicide rates.

The article portrays Richard Shaver as a doting husband driven to desperation, but familicide is the ultimate desperate expression of partners (usually male) trying to maintain power and control over their family members.

It is troubling to me that your article does not draw more attention to this epidemic of an extreme form of domestic violence.

Lior MillerSilver Spring, Md.

More:
The Many Ways of Coping With Alzheimers - The New York Times

Global Brain Monitoring Market Expected to Generate a Value of USD 11.6 Billion by end of Forecast Period, 2019-2024 – ResearchAndMarkets.com – Yahoo…

The "Brain Monitoring Market by Product (Device, MRI, CT, PET, EEG, EMG, MEG, TCD, ICP, Electrode, Paste, Gel, Battery, Cable, Invasive), Disease (TBI, Stroke, Dementia, Epilepsy, Headache, Sleep) & End User (Hospital, Clinic, ASC) - Global Forecasts to 2024" report has been added to ResearchAndMarkets.com's offering.

The global brain monitoring market is expected to reach 11.6 billion by 2024 from USD 8.7 billion in 2019, at a CAGR of 6.1% during the forecast period.

The increasing incidence and prevalence of neurological disorders and rising awareness of neurodegenerative disorders are the key factors driving the brain monitoring market.

Some factors responsible for the growth of this market are the increasing incidence of neurological disorders, rising awareness about neurodegenerative diseases, growth in the number of traumatic brain injuries, and increasing applications of brain monitoring in clinical trials. On the other hand, the shortage of trained professionals to effectively operate brain monitoring devices and unfavorable reimbursement policies are restraining the growth of this market.

The devices segment is expected to account for the largest share of the brain monitoring devices market in 2019.

By product, the global brain monitoring market is categorized into devices and accessories. The devices segment is expected to hold the largest share of the brain monitoring market in 2019. This is mainly due to the rising incidence of neurological, neurodegenerative, psychotic, and sleep disorders; the need for early diagnosis; the availability of innovative portable and wearable home-based monitoring devices; and increasing patient awareness.

The electrodes segment to register the highest growth rate in the forecast period.

The electrodes segment is expected to register the highest growth rate in the forecast period. Technological advancements have enhanced the tissue interface of electrodes and facilitated the development of cost-effective, high-performance electrodes in this market. In addition, the introduction of disposable electrodes has also greatly driven their adoption and the growth of this market segment.

North America to be the largest regional segment in the brain monitoring market during the forecast period.

Story continues

On the basis of region, the global brain monitoring market is divided into North America, Europe, Asia, and the RoW. North America is expected to hold the largest share of the global brain monitoring market in 2019, while Asia is projected to be the fastest-growing region in the forecast period. Growth in the market in Asia is due to the growing geriatric population, the availability of low-cost labor and skilled manpower, increase in disposable incomes, rising prevalence of neurodegenerative disorders, and increasing government emphasis on healthcare reforms in the region.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of revenue numbers for the overall brain monitoring market and its subsegments. This report will also help stakeholders understand the competitive landscape and gain insights to better position their business and make suitable go-to-market strategies. It will also enable stakeholders to understand the pulse of the market and provide them with information on the key market drivers, challenges, and opportunities.

Key Topics Covered:

1 Introduction

1.1 Objectives of the Study

1.2 Market Definition

1.3 Market Scope

1.3.1 Markets Covered

1.3.2 Years Considered for the Study

1.4 Currency

1.5 Limitations

1.6 Market Stakeholders

2 Research Methodology

2.1 Secondary Data

2.1.1 Key Data From Secondary Sources

2.2 Primary Data30

2.2.1 Key Data From Primary Sources

2.3 Market Size Estimation

2.3.1 Bottom-Up Approach

2.3.2 Top-Down Approach

2.4 Market Breakdown and Data Triangulation

2.5 Assumptions for the Study

3 Executive Summary

4 Premium Insights

5 Market Overview

5.1 Introduction

5.2 Market Dynamics

5.2.1 Drivers

5.2.2 Restraints

5.2.3 Opportunities

5.2.4 Challenges

6 Brain Monitoring Market, By Product

6.1 Introduction

6.2 Devices

6.3 Accessories

7 Brain Monitoring Market, By Disease Type

7.1 Introduction

7.2 Traumatic Brain Injuries

7.3 Stroke

7.4 Dementia

7.5 Headache Disorders

7.6 Sleep Disorders

7.7 Epilepsy

7.8 Parkinson's Disease

7.9 Huntington's Disease

7.10 Other Diseases

8 Brain Monitoring Market, By End User

8.1 Introduction

8.2 Hospitals

8.3 Neurology Centers

8.4 Clinics & Ambulatory Surgical Centers

8.5 Diagnostic Centers

8.6 Ambulances

8.7 Other End Users

9 Brain Monitoring Market, By Region

9.1 Introduction

9.2 North America

9.3 Europe

9.4 APAC

9.5 Rest of the World (RoW)

10 Competitive Landscape

10.1 Market Share Analysis

10.2 Competitive Leadership Mapping

10.3 Competitive Situation and Trends

11 Company Profiles

11.1 Introduction

11.2 Natus Medical Inc.

11.3 Nihon Kohden Corporation

11.4 Philips Healthcare

11.5 GE Healthcare

11.6 Siemens Healthineers (A Division of Siemens AG)

11.7 Compumedics Limited

11.8 Medtronic PLC

11.9 CAS Medical Systems, Inc.

11.10 Advanced Brain Monitoring, Inc.

11.11 Drgerwerk AG & Co. KGaA

11.12 Masimo

11.13 Spiegelberg GmbH & Co. Kg

11.14 Cadwell Industries, Inc.

11.15 Neurowave Systems Inc.

11.16 Nonin

11.17 Other Key Players

11.17.1 Integra Lifesciences Corporation

11.17.2 Neurosoft

11.17.3 Rimed

For more information about this report visit https://www.researchandmarkets.com/r/8tae8e

View source version on businesswire.com: https://www.businesswire.com/news/home/20191227005174/en/

Contacts

ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

See original here:
Global Brain Monitoring Market Expected to Generate a Value of USD 11.6 Billion by end of Forecast Period, 2019-2024 - ResearchAndMarkets.com - Yahoo...

Neurologist Deborah Boland Named Physician of the Year – Patch.com

The Hillsborough County Osteopathic Medical Society (HCOMS) has named Dr. Deborah Boland, D.O., MSPT, Neurologist, Diplomate of the American Board of Psychiatry and Neurology, and owner of Be Mobile Neurology, as their "Physician of the Year" for 2019. This prestigious award is presented to a Doctor of Osteopathic Medicine (D.O.) who has made significant contributions to both the osteopathic profession and the local community. Dr. Boland is one of only a handful of Movement Disorder specialists in the Tampa Bay area and is a pioneer in the mobile delivery of neurological services.

Dr. Boland said, "I am so honored and humbled to be recognized by my colleagues and friends with this award. Healthcare is rapidly changing, and I'm proud to be leading the movement back to patient-centered, individualized care. Through my practice, Be Mobile Neurology, I am working to offer a more personalized and affordable approach to healthcare, improving outcomes for my patients."

Over the course of her medical career, Dr. Boland witnessed the limitations and stress that traditional physician office visits placed on both patients with neurological issues and their caregivers. Through in-home visits and telemedicine, Be Mobile Neurology presents a solution, offering patients a membership model for healthcare services that allows them to receive focused attention in a comfortable setting. Be Mobile Neurology is the only mobile neurology practice in Tampa Bay and is leading trends nationally.

Dr. Boland started in healthcare as a Physical Therapist, receiving her master's degree in Physical Therapy from Andrews University in Berrien Springs, Michigan, and practicing for 10 years before going to medical school. Dr. Boland earned her medical degree from Des Moines University College of Osteopathic Medicine, which has a rich osteopathic history and is one of the oldest osteopathic medical schools in the country.

Following medical school, she completed her internship and neurology residency at the University of Illinois College of Medicine/OSF Saint Francis Medical Center. Dr. Boland went on to complete fellowship training specializing in Movement Disorders at Duke University, and she served as an Assistant Professor of the Movement Disorders Center at Georgia Regents University's Department of Neurology.

Since January 2018, Dr. Boland has served as a Governor on the Hillsborough County Osteopathic Medical Society Board. She also is a member of the International Parkinson and Movement Disorder Society, the American Academy of Neurology, the American Osteopathic Association, and Working Women of Tampa Bay.

If you're interested in learning more about Dr. Boland or her ground-breaking neurological practice, please call (813) 981-4403 or visit http://www.bemobileneurology.com.

Go here to see the original:
Neurologist Deborah Boland Named Physician of the Year - Patch.com